Freenome

📍 South San Francisco, United States🗓 Founded 2014👥 516 employees💰 Last funded 2021
Biotechnology Research🌐 freenome.com
Website LinkedIn
Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.
10
Total investors
2
Early stage
7
Mid stage
1
Late stage
2014
Founded

Investors

10 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
10
Investor activity2015–2021 · investors recorded per year
2015220172201812019420211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Freenome?
Freenome has 10 investors on record on gritt.io, including 2 early-stage backers, 7 mid-stage and 1 late-stage investors.
When did Freenome last raise funding?
The most recent investment in Freenome recorded on gritt.io was in 2021.
When was Freenome founded?
Freenome was founded in 2014.
What industry is Freenome in?
Freenome operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Freenome based?
Freenome is headquartered in South San Francisco, United States.